Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Journal of Immunology (Baltimore, Md. : 1950)|September 3, 2013
Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapyEmilie Laprevotte, Gregory Voisin, Loïc Ysebaert, et al.
Blood|May 6, 2004
Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomainsChristine Bezombes, Solène Grazide, Céline Garret, et al.
The Journal of Biological Chemistry|January 17, 2007
UVA induces granzyme B in human keratinocytes through MIF: implication in extracellular matrix remodelingHélène Hernandez-Pigeon, Christine Jean, Alexandra Charruyer, et al.
Blood|December 8, 2009
Rituximab inhibits B-cell receptor signalingSamar Kheirallah, Pierre Caron, Emilie Gross, et al.
Journal of Molecular Biology|April 6, 2005
hMutS alpha is protected from ubiquitin-proteasome-dependent degradation by atypical protein kinase C zeta phosphorylationHélène Hernandez-Pigeon, Anne Quillet-Mary, Thierry Louat, et al.
Biomarker Research|December 10, 2020
Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapseSarah Cadot, Carine Valle, Marie Tosolini, et al.
Leukemia Research|December 25, 2012
Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemiaEmilie Laprevotte, Loïc Ysebaert, Christian Klein, et al.
BMC Cancer|August 16, 2019
Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemiaMartin Gauthier, Françoise Durrieu, Elodie Martin, et al.
Plos Medicine|July 22, 2024
New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modelingSarah Cadot, Chloe Audebert, Charlotte Dion, et al.
Journal of Hypertension|January 21, 2025
Ibrutinib pharmacokinetics in B-lymphoproliferative disorders discloses exposure-related incidence of hypertensionLoïc Ysebaert, Caroline Protin, Lucie Obéric, et al.
Pageof 4